Legal Disclaimer
Last updated: March 2026
IMPORTANT: Biocat is NOT a financial advisor, investment firm, or broker-dealer.
All data, scores, signals, and analysis provided by this platform are strictly for informational and educational purposes only. Nothing on this platform constitutes financial advice, investment advice, trading advice, or any other form of professional advice.
1. No Financial Advice
Biocat aggregates publicly available data and applies quantitative models to generate scores and signals. These outputs:
- Are not recommendations to buy, sell, or hold any security
- Are not personalised investment advice under Directive 2014/65/EU (MiFID II)
- Do not take into account your individual financial situation, risk tolerance, or investment objectives
- Should not be the sole basis for any investment decision
You are solely responsible for your own investment decisions and should consult a qualified, licensed financial advisor before making any trades.
2. No Investment Recommendations (MiFID II)
Under the Markets in Financial Instruments Directive II (Directive 2014/65/EU) and its delegated regulations, Biocat does not provide:
- Investment recommendations as defined in Article 3(1)(35) of MiFID II
- Investment advice as defined in Article 4(1)(4) of MiFID II
- Portfolio management or any regulated investment service
Biocat is not authorised or regulated by the Comissão do Mercado de Valores Mobiliários (CMVM), the Portuguese securities market regulator, nor by the European Securities and Markets Authority (ESMA), nor by any other national competent authority in the EU.
The composite scores generated by Biocat are algorithmic outputs based on publicly available data. They do not constitute "investment research" within the meaning of Article 36 of Commission Delegated Regulation (EU) 2017/565.
3. Market Abuse Regulation (MAR)
Under Regulation (EU) No 596/2014 (Market Abuse Regulation):
- Biocat does not produce or disseminate investment recommendations within the meaning of MAR Article 20
- Users must not use Biocat data or signals to engage in market manipulation (Article 12) or insider dealing (Article 8)
- Any pattern of trading based solely on automated signals that could constitute market manipulation is strictly prohibited
4. Risk Warnings
Investing in biotech and pharmaceutical stocks involves significant risk, including:
- Binary event risk: FDA decisions (PDUFA dates, AdCom votes) can cause stock prices to move 30-80% in a single day, in either direction
- Clinical trial failure: The majority of drug candidates fail in clinical trials. Phase 2 success rates are approximately 30%, and Phase 3 success rates approximately 50%
- Total loss of capital: Small-cap biotech companies can lose most or all of their value following negative regulatory decisions or trial failures
- Liquidity risk: Small-cap biotech stocks may have low trading volume, making it difficult to exit positions
- Dilution risk: Pre-commercial biotech companies frequently issue new shares to fund operations, diluting existing shareholders
Past performance is not indicative of future results. Historical backtest data shown on the platform is based on past market conditions that may not recur.
5. Data Accuracy and Limitations
Biocat sources data from publicly available third-party providers including:
- SEC EDGAR (regulatory filings)
- ClinicalTrials.gov (clinical trial data)
- Yahoo Finance and Finnhub (market data)
- openFDA (drug and adverse event data)
While we make reasonable efforts to ensure accuracy, we cannot guarantee that:
- Data is complete, current, or free from errors
- PDUFA dates or trial completion dates are accurate (these are frequently delayed or changed)
- Scores and signals reflect real-time market conditions
- Third-party data sources are available or functioning correctly at all times
Always verify critical information from primary sources before making investment decisions.
6. AI and Algorithmic Outputs
In accordance with the principles of the EU Artificial Intelligence Act (Regulation (EU) 2024/1689):
- Biocat uses AI-powered natural language processing (FinBERT) for sentiment analysis of news headlines
- Composite scores are generated by algorithmic models combining multiple quantitative factors
- These AI-generated outputs are probabilistic estimates, not certainties
- The models may contain biases, produce errors, or fail to account for material information
- Users should exercise their own judgement and not rely solely on AI-generated scores
7. Jurisdiction and Governing Law
Biocat is operated from Portugal and is subject to:
- Portuguese law as the primary governing jurisdiction
- EU regulations with direct effect, including GDPR, MAR, and MiFID II where applicable
- The Portuguese Consumer Protection Act (Lei n.º 24/96) for consumer rights
- The Portuguese Securities Code (Código dos Valores Mobiliários) regarding securities-related disclaimers
Any disputes arising from the use of this platform shall be submitted to the courts of Lisbon, Portugal, without prejudice to any mandatory consumer protection provisions that may grant jurisdiction to the courts of the consumer's place of residence within the EU.
8. Consumer Rights (EU)
Under Directive 2011/83/EU (Consumer Rights Directive) as transposed into Portuguese law (Decreto-Lei n.º 24/2014):
- Free accounts: no financial commitment, you may stop using the service at any time
- Paid subscriptions: you have a 14-day right of withdrawal from the date of subscription, unless you have expressly consented to the immediate provision of digital content and acknowledged the loss of the right of withdrawal
- You may exercise your right of withdrawal by contacting us at the email address below
9. Digital Services Act (DSA)
In compliance with Regulation (EU) 2022/2065 (Digital Services Act):
- Biocat is an information society service provider established in Portugal
- Point of contact for users and authorities: g.cecinelli@gmail.com
- We do not host user-generated content; all data is sourced from public regulatory and financial databases
- Illegal content or misuse of the platform can be reported to the contact email above
10. Limitation of Liability
To the maximum extent permitted by applicable Portuguese and EU law:
- Biocat and its operators shall not be liable for any direct, indirect, incidental, consequential, or special damages arising from your use of the platform
- This includes, without limitation: trading losses, lost profits, loss of data, or damages resulting from reliance on scores, signals, or data provided by the platform
- Our total aggregate liability to you shall not exceed the amount you have paid for the service in the 12 months preceding the claim
Nothing in this disclaimer excludes or limits liability for fraud, gross negligence, or any liability that cannot be excluded under mandatory provisions of Portuguese or EU law.
11. Regulatory Status
Biocat is not:
- A credit institution or investment firm under MiFID II
- Registered with the CMVM (Comissão do Mercado de Valores Mobiliários)
- Registered with the Banco de Portugal
- Registered with ESMA or any other EU national competent authority
- A provider of investment advice, portfolio management, or any other regulated financial service
12. Changes to This Disclaimer
We may update this legal disclaimer at any time. Material changes will be communicated via the platform. Continued use after changes constitutes acceptance of the updated terms.
13. Contact
Biocat
Operated from Lisbon, Portugal
Legal inquiries: g.cecinelli@gmail.com
See also: Terms of Service · Privacy Policy